Trinity Biotech plc Total Assets
Trinity Biotech plc total assets. Based on the latest financial reports, Trinity Biotech plc (TRIB) holds total assets worth $105.17 Million USD as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see TRIB company net worth for the company's overall valuation and market capitalisation.
Total Assets of Trinity Biotech plc (1993–2025)
Total assets of Trinity Biotech plc from 1993 to 2025. This chart illustrates how Trinity Biotech plc's total assets have evolved over time, based on quarterly financial data. See Trinity Biotech plc stock quote for real-time trading data and today's change.
Trinity Biotech plc - Asset Composition Analysis
Trinity Biotech plc Total Assets Breakdown (December 2025)
Trinity Biotech plc total assets breakdown as of December 2025. Trinity Biotech plc's total assets of $105.17 Million consist of 34.1% current assets and 65.9% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 4.9% |
| Accounts Receivable | $10.28 Million | 9.8% |
| Inventory | $18.83 Million | 17.9% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $43.02 Million | 40.9% |
| Goodwill | $13.97 Million | 13.3% |
Asset Composition Trend (1993–2025)
This chart illustrates how Trinity Biotech plc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore TRIB net working capital ratio to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Trinity Biotech plc's current assets represent 34.1% of total assets in 2025, a decrease from 46.9% in 1993.
- Cash Position: Cash and equivalents constituted 4.9% of total assets in 2025, down from 18.4% in 1993.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 53.0% of total assets, an increase from 34.0% in 1993.
- Asset Diversification: The largest asset category is intangible assets at 40.9% of total assets.
Trinity Biotech plc Competitors by Total Assets
Key competitors of Trinity Biotech plc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Shenzhen New Industries Biomedical
SHE:300832
|
China | CN¥9.58 Billion |
|
Double Medical Technology Inc
SHE:002901
|
China | CN¥5.03 Billion |
|
BMC Medical Co. Ltd. A
SHE:301367
|
China | CN¥3.59 Billion |
|
SS Innovations International Inc. Common Stock
NASDAQ:SSII
|
USA | $96.98 Million |
|
Emvision Medical Devices Ltd
AU:EMV
|
Australia | AU$24.94 Million |
|
Sequana Medical NV
BR:SEQUA
|
Belgium | €14.57 Million |
|
Hironic Co. Ltd
KQ:149980
|
Korea | ₩80.01 Billion |
|
DRGEM Corporation
KQ:263690
|
Korea | ₩131.65 Billion |
Trinity Biotech plc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.25 | 1.17 | 0.77 |
| Quick Ratio | 0.12 | 0.50 | 0.44 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $-105.31 Million | $5.05 Million | $-24.16 Million |
Trinity Biotech plc - Advanced Valuation Insights
This section examines the relationship between Trinity Biotech plc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 5.75 |
| Latest Market Cap to Assets Ratio | 0.05 |
| Asset Growth Rate (YoY) | 1.8% |
| Total Assets | $105.17 Million |
| Market Capitalization | $5.33 Million USD |
Valuation Analysis
Below Book Valuation: The market values Trinity Biotech plc's assets below their book value (0.05x), which may indicate investor concerns about asset quality or future growth.
Positive Asset Growth: Trinity Biotech plc's assets grew by 1.8% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for Trinity Biotech plc (1993–2025)
The table below shows the annual total assets of Trinity Biotech plc from 1993 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $105.17 Million | +1.82% |
| 2024-12-31 | $103.29 Million | +73.79% |
| 2023-12-31 | $59.44 Million | -35.47% |
| 2022-12-31 | $92.10 Million | -22.53% |
| 2021-12-31 | $118.89 Million | -8.82% |
| 2020-12-31 | $130.40 Million | -0.51% |
| 2019-12-31 | $131.07 Million | -13.33% |
| 2018-12-31 | $151.24 Million | -21.48% |
| 2017-12-31 | $192.62 Million | -22.83% |
| 2016-12-31 | $249.59 Million | -30.47% |
| 2015-12-31 | $358.96 Million | +47.82% |
| 2014-12-31 | $242.84 Million | +7.22% |
| 2013-12-31 | $226.49 Million | +14.73% |
| 2012-12-31 | $197.41 Million | +15.11% |
| 2011-12-31 | $171.50 Million | +6.60% |
| 2010-12-31 | $160.87 Million | +21.46% |
| 2009-12-31 | $132.44 Million | +2.27% |
| 2008-12-31 | $129.51 Million | -40.04% |
| 2007-12-31 | $215.98 Million | -13.31% |
| 2006-12-31 | $249.13 Million | +34.96% |
| 2005-12-31 | $184.60 Million | +22.39% |
| 2004-12-31 | $150.83 Million | +27.72% |
| 2003-12-31 | $118.09 Million | +32.29% |
| 2002-12-31 | $89.27 Million | +15.89% |
| 2001-12-31 | $77.03 Million | +14.57% |
| 2000-12-31 | $67.23 Million | +49.26% |
| 1999-12-31 | $45.04 Million | +0.09% |
| 1998-12-31 | $45.00 Million | +82.93% |
| 1997-12-31 | $24.60 Million | +83.58% |
| 1996-12-31 | $13.40 Million | +45.65% |
| 1995-12-31 | $9.20 Million | +196.77% |
| 1994-12-31 | $3.10 Million | -36.73% |
| 1993-12-31 | $4.90 Million | -- |
About Trinity Biotech plc
Trinity Biotech plc, together with its subsidiaries, develops, acquires, manufactures, and markets medical diagnostic products for the clinical laboratory and point-of-care (POC) segments of the diagnostic market in the Americas, Asia, Africa, and Europe. The company offers clinical laboratory products, including diagnostic tests and instrumentation, which detects infectious diseases; sexually tr… Read more